Germany's ElexoPharm in CVD collaboration with Merck & Co, potentially worth 33.8 million euros
US drugs giant Merck & Co has entered into a collaboration with German firm ElexoPharm GmbH to develop and commercialize novel candidates targeting aldosterone synthase for the potential treatment of cardiovascular disease.
Under the terms of the deal, Merck will pay ElexoPharm an upfront payment of 1.5 million euros ($1.9 million). In addition, ElexoPharm is eligible to receive up to an additional 32.3 million euros if specific development, regulatory and commercial milestones are achieved for a candidate and royalties on net sales of any products resulting from the collaboration. Merck is responsible for development, regulatory filings, manufacturing and commercialization activities.
'This agreement marks a major milestone in ElexoPharm's relatively recent company history," said Axel Koch, managing director of ElexoPharm GmbH.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze